• HBM1007 is a fully-human monoclonal antibody targeting CD73
• HBM1007 is generated from Harbour Mice^®  H2L2 platform
• With unique epitopes to recognize CD73, HBM1007 works through dual modes of action

Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 19, 2022

Harbour BioMed (Company, HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration of the United States (FDA) to initiate clinical trials in the U.S. for monoclonal antibody HBM1007, a fully-human antibody targeting CD73, generated from Harbour Mice^®.

Generated from Harbour Mice^® H2L2 transgenic mice platform, HBM1007 is an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. With unique epitopes to recognize CD73, HBM1007 works through dual modes of action. On the one hand, it can block the enzymatic activity of both membrane and soluble CD73 independent of AMP concentration, suggesting its sustainable activity in TME. On the other hand, it reduces the surface expression of CD73. As a result, both enzymatic and non-enzymatic dependent functions of CD73 were significantly reduced.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^®, HBICE^® with single B cell cloning platform, the antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com